Opendata, web and dolomites

GUT-SEQ SIGNED

Single-cell analysis of intestinal lymphocytes reveals targets for treatment of inflammatory bowel disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GUT-SEQ project word cloud

Explore the words cloud of the GUT-SEQ project. It provides you a very rough idea of what is the project "GUT-SEQ" about.

responders    patients    discovery    play    parallels    rationale    therapies    lymphocyte    unfold    treatment    mucosal    therapy    seminal    inflammatory    unexplored    signatures    intestinal    am    ilcs    rna    made    diseases    assessments    lymphoid    clinical    redundancy    performing    materials    innate    molecular    summary    cell    inflammation    network    treatments    characterization    combines    burden    perform    patient    ibd    contributions    adaptive    lymphocytes    samples    immunological    transformation    personalize    single    disease    complementarity    acting    immune    roles    hampering    pressing    antigen    beneficial    2012    immunity    concert    largely    critical    lacking    dissection    immunol    mechanisms    bowel    2011    position    building    revealing    2013    longitudinal    cells    drug    biological    strategies    sequencing    health    opportunity    unprecedented    human    resident    provides    2016    unveil    conventional    nat    feasible    equivalents    fraction    tissue    compartments    golden    constitutes    reveal    global   

Project "GUT-SEQ" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 1˙500˙000 €
 EC max contribution 1˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-07-01   to  2025-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 1˙500˙000.00

Map

 Project objective

Inflammatory bowel disease (IBD) constitutes an increasing global health burden, yet effective treatments are lacking. Hampering rationale treatment strategies, the human intestinal immune system remains largely unexplored. I have made seminal contributions to the discovery and characterization of innate lymphoid cells (ILCs) (Nat Immunol 2011, 2013 and 2016, Immunity 2012), revealing that in addition to antigen-specific adaptive T cells, innate equivalents play important roles in mucosal immunity. Determining the complementarity and redundancy of these two lymphocyte systems, acting in concert, is important for our understanding of inflammatory diseases and the development of novel therapies. For this proposal, I am in the beneficial position of having access to unique patient samples as well as established methods for single-cell RNA-sequencing to perform an ambitious and comprehensive molecular dissection of the human intestinal lymphocyte compartments in IBD. With this approach, I will determine parallels between known, and identify novel, subsets of tissue-resident, inflammation-associated, innate and adaptive lymphocytes. Building on this unprecedented molecular characterization, we will take on some of the most pressing clinical problems in IBD by performing longitudinal assessments of intestinal lymphocytes from IBD patients on conventional and biological treatments. As only a fraction of patients respond to treatment, this approach provides a golden opportunity to unveil immunological signatures of treatment response and “drug-induced transformation” of inflammation in non-responders. Furthermore, we will unfold critical disease mechanisms and reveal novel therapy targets and how they can be used to personalize treatment. In summary, my ambitious, yet feasible, proposal combines state-of-the-art technology with access to unique patient materials. My studies are likely to advance our understanding of the complex intestinal lymphocyte network in IBD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GUT-SEQ" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GUT-SEQ" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More